肺移植拒絶反応:治療薬開発パイプライン分析

Global Markets Directが発行した調査報告書(GMDHC9882IDB)
◆英語タイトル:Lung Transplant Rejection - Pipeline Review, H2 2017
◆商品コード:GMDHC9882IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2017年11月14日
◆ページ数:57
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における肺移植拒絶反応の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・肺移植拒絶反応の概要
・肺移植拒絶反応治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・肺移植拒絶反応パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・肺移植拒絶反応治療薬開発に取り組んでいる企業:企業別製品パイプライン
・肺移植拒絶反応治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Lung Transplant Rejection – Pipeline Review, H2 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Lung Transplant Rejection – Pipeline Review, H2 2017, provides an overview of the Lung Transplant Rejection (Immunology) pipeline landscape.

Lung transplantation is the therapy used in various lung diseases. Lung transplant replaces an injured or diseased lung with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted lung as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Lung Transplant Rejection – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Lung Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lung Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Lung Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 1 and 6 respectively.

Lung Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Lung Transplant Rejection (Immunology).
- The pipeline guide reviews pipeline therapeutics for Lung Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Lung Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Lung Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Lung Transplant Rejection (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Lung Transplant Rejection (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Lung Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lung Transplant Rejection – Overview 6
Lung Transplant Rejection – Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Products under Development by Companies 9
Lung Transplant Rejection – Therapeutics Assessment 10
Assessment by Target 10
Assessment by Mechanism of Action 12
Assessment by Route of Administration 14
Assessment by Molecule Type 16
Lung Transplant Rejection – Companies Involved in Therapeutics Development 18
Apeptico Forschung und Entwicklung GmbH 18
Astellas Pharma Inc 18
Dompe Farmaceutici SpA 18
Kamada Ltd 19
MimeTech Srl 19
Novartis AG 20
Quark Pharmaceuticals Inc 20
Lung Transplant Rejection – Drug Profiles 22
alpha-1 proteinase inhibitor (human) – Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
FX-06 – Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
MT-8 – Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
QPI-1024 – Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
QPLI-1 – Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
R-554 – Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
R-801 – Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
reparixin – Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
solnatide – Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
tacrolimus – Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
tiprelestat – Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Zortress – Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Lung Transplant Rejection – Dormant Projects 48
Lung Transplant Rejection – Product Development Milestones 49
Featured News & Press Releases 49
Oct 09, 2017: Quark Pharmaceuticals to Present Preclinical Efficacy Data on Inhaled siRNA Co-Developed with Biocon for Prevention of Primary Graft Dysfunction following Lung Transplantation at the 6th Annual RNAi China Conference 49
Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection 49
Dec 09, 2015: Quark announces issue of U.S. patent for novel treatment of lung transplantation associated injury 51
Jun 22, 2015: Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection 51
Mar 12, 2015: Elafin combined with cyclosporine promises to overcome limitations of cyclosporine for preventing irreversible damage to transplanted organs 52
Apr 17, 2013: APEPTICO initiates phase II clinical trial with AP301 in patients with primary graft dysfunction following lung transplantation 53
Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program 53
Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria 54
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57

List of Tables
Number of Products under Development for Lung Transplant Rejection, H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Products under Development by Companies, H2 2017 9
Number of Products by Stage and Target, H2 2017 11
Number of Products by Stage and Mechanism of Action, H2 2017 13
Number of Products by Stage and Route of Administration, H2 2017 15
Number of Products by Stage and Molecule Type, H2 2017 17
Lung Transplant Rejection - Pipeline by Apeptico Forschung und Entwicklung GmbH, H2 2017 18
Lung Transplant Rejection - Pipeline by Astellas Pharma Inc, H2 2017 18
Lung Transplant Rejection - Pipeline by Dompe Farmaceutici SpA, H2 2017 19
Lung Transplant Rejection - Pipeline by Kamada Ltd, H2 2017 19
Lung Transplant Rejection - Pipeline by MimeTech Srl, H2 2017 20
Lung Transplant Rejection - Pipeline by Novartis AG, H2 2017 20
Lung Transplant Rejection - Pipeline by Quark Pharmaceuticals Inc, H2 2017 21
Lung Transplant Rejection - Dormant Projects, H2 2017 48

List of Figures
Number of Products under Development for Lung Transplant Rejection, H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Number of Products by Top 10 Targets, H2 2017 10
Number of Products by Stage and Top 10 Targets, H2 2017 10
Number of Products by Top 10 Mechanism of Actions, H2 2017 12
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 12
Number of Products by Routes of Administration, H2 2017 14
Number of Products by Stage and Routes of Administration, H2 2017 14
Number of Products by Molecule Types, H2 2017 16
Number of Products by Stage and Molecule Types, H2 2017 16

【レポートのキーワード】

肺移植拒絶反応

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 肺移植拒絶反応:治療薬開発パイプライン分析(Lung Transplant Rejection - Pipeline Review, H2 2017)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆